The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for LNZ100 (aceclidine 1.75% ophthalmic solution) for the treatment of presbyopia. LNZ100 is a single-use, ...
Presbyopia is caused by a stiffening in the lens of the eye that develops in people after the age of 40, and affects an estimated 128 million people in the US. AbbVie is recommending Vuity ...
The FDA has approved the first and so far only pharmacological treatment for presbyopia, a sight condition that typically starts in middle age and involves difficulty in focusing on near objects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback